It is funny, even after a double short latte the facts
seem buried somewhere in my noggin. I even wrote to
Genzyme a while back, and got a very nice letter spelling
at all out. Somebody, probably Peter, posted that Papa
could take back any of the tracking stocks for an extra
30%, but the point is moot. You are right, Papa's gain...
where the profits might come off the table, maybe 3x,
certainly long before 100x, though <g>.
What I would like to know, is how the stock was driven down
to $7 in August. Clearly doubling your money from that low
was a good trade that I think some of us made. I do not
know where the next good trade will be. I suppose hoping
to buy at $7 again is just as much of a gamble as holding
it now for $30.
For sure, I really don't know anything.
And that is the most remarkable thing to me about
the big biotech rally this past year--that any bozo
could come in, recognize the sector had been dead for
too long, see a great place for the money to rotate,
and hop on for a nice ride. All you had to have was
a little enthusiasm and a brokerage account in 1999,
and have some sort of an exit strategy this year.
(my own was nearly bungled)
And now to have the luxury to be in some biotechs
which are paid for several times over--and actually see
them through is pretty nifty.
Gizzmo could be a terrific stock to hold awhile,
and I'll probably buy back my shares if I see a
dip--and after I have my little daytrading fling.
For now, I don't really like holding a lot of stocks
overnight. Neither am I sure about laying out cash
for 1000 SEPR, then fretting over the level II.
So far so good, but it is a little nutty I think.
Great fun tho.
While we are on gzmo--I was cruising some patent
website a couple months ago, and noticed that there
were a few patents assigned to Dana-Farber--antigens.
That is a homework assignment I should finish.
Loved the Purdue Pharma press release, neat. |
